

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 263/58, 213/74, 239/42, A61K 31/42	A1	(11) International Publication Number: WO 95/17394 (43) International Publication Date: 29 June 1995 (29.06.95)
(21) International Application Number: PCT/EP94/04112 (22) International Filing Date: 10 December 1994 (10.12.94) (30) Priority Data: 9326171.7 22 December 1993 (22.12.93) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC. [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): CANTELLO, Barrie, Christian, Charles [GB/GB]; SmithKline Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). HAIGH, David [GB/GB]; SmithKline Beecham Pharmaceuticals, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). (74) Agent: RUTTER, Keith; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: HETEROCYCLIC DERIVATIVES AND THEIR USE IN PHARMACEUTICALS		
(57) Abstract		
<p>A compound of the formula (I): $A^1-X-(CH_2)_n-O-A^2-A^3-Y^1$ or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein: A^1 represents a substituted or unsubstituted aromatic heterocyclyl group; A^2 represents a benzene ring having three optional substituents; A^3 represents a moiety of formula $-(CH_2)_m-CH(OR^1)-$ wherein m represents an integer in the range of from 1 to 5 and R^1 represents a moiety $-(CH_2)_x-Y^1-(CH_2)_y-T$ wherein Y^1 represents O, NR^0 wherein R^0 is H, alkyl or alkylcarbonyl or Y^1 is S, T represents a phenyl group optionally substituted with up to 3 substituents selected from halo, alkyl and alkoxy, x represents an integer in the range of from 2 to 5 and y represents zero or an integer in the range of from 1 to 5; or A^3 represents a moiety of formula $-(CH_2)_{m-1}-CH=C(OR^1)-$ wherein R^1 and m are as defined above; R^2 represents OR^3 wherein R^3 represents hydrogen, alkyl, aryl or aralkyl or R^2 represents an aromatic heterocyclyl group or $-NR^4R^5$ wherein R^4 and R^5 each independently represent hydrogen, alkyl or alkylcarbonyl or R^4 and R^5 together with the nitrogen atom to which they are attached form a heterocyclic ring, providing that R^2 represents an aromatic heterocyclyl group only when Y as defined below represents a bond; X represents NR wherein R represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; Y represents C=O or C=S or a bond providing that Y represents a bond only when R^2 represents the above mentioned aromatic heterocyclyl group; and n represents an integer in the range of from 2 to 6; a process for preparing such a compound, a composition comprising such a compound and the use of such a compound and composition in medicine.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				


HETEROCYCLIC DERIVATIVES AND THEIR USE IN PHARMACEUTICALS

This invention relates to certain novel compounds, to a process for preparing such compounds, to pharmaceutical compositions containing such compounds and to
 5 the use of such compounds and compositions in medicine.

It has now surprisingly been discovered that certain novel compounds show particularly good blood-glucose lowering activity and are therefore of potential use in the treatment and/or prophylaxis of hyperglycaemia and are of particular use in the treatment of Type II diabetes.

10 These compounds are also indicated to be of potential use for the treatment and/or prophylaxis of other diseases including hyperlipidaemia and hypertension. They are also indicated to be of use in the treatment and/or prophylaxis of cardiovascular disease, especially atherosclerosis. In addition these compounds are considered to be useful for treating certain eating disorders,
 15 in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating, such as anorexia nervosa, and disorders associated with over-eating, such as obesity and anorexia bulimia.

Accordingly, the present invention provides a compound of formula (I):



(I)

or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof,
 25 and/or a pharmaceutically acceptable solvate thereof, wherein:
 A^1 represents a substituted or unsubstituted aromatic heterocyclyl group;
 A^2 represents a benzene ring having three optional substituents;
 A^3 represents a moiety of formula $-(CH_2)_m-CH(OR^1)-$ wherein m represents an integer in the range of from 1 to 5 and R^1 represents a moiety
 30 $-(CH_2)_x-Y^1-(CH_2)_y-T$ wherein Y^1 represents O, NR° wherein R° is H, alkyl or alkylcarbonyl or Y^1 is S, T represents a phenyl group optionally substituted with up to 3 substituents selected from halo, alkyl and alkoxy, x represents an integer in the range of from 2 to 5 and y represents zero or an integer in the range of from 1 to 5; or

A³ represents a moiety of formula $-(CH_2)_{m-1}-CH=C(OR^1)-$ wherein R¹ and m are as defined above;

R² represents OR³ wherein R³ represents hydrogen, alkyl, aryl or aralkyl or R² represents an aromatic heterocyclyl group or $-NR^4R^5$ wherein R⁴ and R⁵ each independently represent hydrogen, alkyl or alkylcarbonyl or R⁴ and R⁵ together with the nitrogen atom to which they are attached form a heterocyclic ring, providing that R² represents an aromatic heterocyclyl group only when Y as defined below represents a bond ;

X represents NR wherein R represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;

Y represents C=O or C=S or a bond providing that Y represents a bond only when R² represents the above mentioned aromatic heterocyclyl group; and n represents an integer in the range of from 2 to 6.

Suitable aromatic heterocyclyl groups include substituted or unsubstituted, single or fused ring aromatic heterocyclyl groups comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen.


Favoured aromatic heterocyclyl groups include substituted or unsubstituted single ring aromatic heterocyclyl groups having 5 to 7 ring atoms, preferably 5 or 6 ring atoms.

In particular, the aromatic heterocyclyl group comprises 1, 2 or 3 heteroatoms, especially 1 or 2, selected from oxygen, sulphur or nitrogen.


Suitable values for A¹ when it represents a 5- membered aromatic heterocyclyl group include thiazolyl and oxazolyl, especially oxazolyl.

Suitable values for A¹ when it represents a 6- membered aromatic heterocyclyl group include pyridyl or pyrimidinyl, especially pyridyl.


Preferably, A¹ represents a moiety of formula (a), (b) or (c):



(a)



(b)



(c)

wherein:


R^6 and R^7 each independently represents a hydrogen or halogen atom, an alkyl or alkoxy group or a substituted or unsubstituted aryl group or when R^6 and R^7 are each attached to adjacent carbon atoms, then R^6 and R^7 together with the carbon atoms to which they are attached form a benzene ring wherein each carbon atom represented by R^6 and R^7 together is substituted or unsubstituted; and in the moiety of formula (a) X^1 represents oxygen or sulphur.

Aptly, A^1 represents a moiety of the abovedefined formula (a).

Aptly, A^1 represents a moiety of the abovedefined formula (b).

Aptly, A^1 represents a moiety of the abovedefined formula (c).


A particular form of moiety (c) is a moiety (c'):



(c')

wherein R^6 and R^7 are as defined in relation to formula (c).

In one favoured aspect R^6 and R^7 together represent a moiety of formula (d):



(d)

wherein R^{8a} and R^{8b} each independently represent hydrogen, halogen, substituted or unsubstituted alkyl or alkoxy.

Suitably, R^{8a} and R^{8b} each independently represent hydrogen, halogen, alkyl or alkoxy. Favourably, R^{8a} represents hydrogen. Favourably, R^{8b} represents hydrogen. Preferably, R^{8a} and R^{8b} both represent hydrogen.


In a further favoured aspect R^6 and R^7 each independently represent hydrogen, alkyl or a substituted or unsubstituted phenyl group and more favourably, R^6 and R^7 each independently represent hydrogen, alkyl or phenyl.

Preferably, for the moiety of formula (a), R^6 and R^7 together represent
5 the moiety of formula (d).

Preferably, for the moieties of formula (b), (c) or (c'), R^6 and R^7 both represent hydrogen.

Optional substituents for A^2 are selected from the group consisting of: halogen, substituted or unsubstituted alkyl and alkoxy.

10 Favourably, A^2 represents a moiety of formula (e):



(e)

15

wherein R^{10} and R^{11} each independently represent hydrogen, halogen, substituted or unsubstituted alkyl or alkoxy.

Suitably, R^{10} and R^{11} each independently represent hydrogen, halogen, alkyl or alkoxy.

20 When R^{10} or R^{11} represent alkoxy, a suitable alkoxy group is a methoxy group.

Preferably, R^{10} and R^{11} each represent hydrogen.

Suitably, A^3 represents a moiety of formula $-(CH_2)_m-CH(OR^1)-$.

Suitably, A^3 represents a moiety of formula $-CH=C(OR^1)-$.

25 Suitably, x represents 2.

An example of y is 1.

Suitably y represents zero.

Suitably, Y^1 represents O.

Suitably, T represents phenyl.

30 Favourably, R^1 represents a moiety of formula $-CH_2-CH_2-O$ -phenyl.

Suitably, R^3 represents hydrogen or alkyl.

When R^3 is alkyl, examples of R^3 include methyl and ethyl.

When R^2 is an aromatic heterocyclyl group it is suitably a single ring aromatic heterocyclyl group having 5 ring atoms, which ring atoms comprise nitrogen and optionally 1, 2 or 3 additional hetero atoms; examples include 1, 2, 4-triazole; 1, 2, 4-oxadiazole and tetrazolyl; generally the aromatic heterocyclyl group is C-linked.

Suitable substituents on the aromatic heterocyclyl group include alkyl, aryl, alkoxy and halo, an example of a substituent is methyl.

When $-NR^4R^5$ or $-NR^5R^1$ represents a heterocyclic ring, favoured heterocyclic rings are saturated or unsaturated, fused or monocyclic heterocyclic rings comprising 5, 6 or 7 ring atoms and optionally comprising 1 or 2 additional hetero-atoms, selected from O, S or N, in each ring. Favoured rings are saturated rings. Favoured rings are monocyclic rings. Favoured, additional hetero-atoms are N or O. Examples of such heterocyclic rings include N-pyrrolidinyl, N-piperidinyl and N-morpholinyl.

A further example of NR^4R^5 is NH_2 .

Suitably, R^2 represents NR^4R^5 .

Preferably R^2 is OR^3 .

Suitably when R^2 represents OR^3 wherein R^3 represents hydrogen, alkyl, aryl or aralkyl or R^2 represents $-NR^4R^5$, Y is CO or CS; preferably, Y is CO.

When R^2 is an aromatic heterocyclyl group, Y is a bond.

Suitably, R represents hydrogen or alkyl.

When R is acyl, suitable acyl groups include alkylcarbonyl groups, such as acetyl.

Suitably, m represents 1 or 2.

Favourably, m is 1.

Favourably, n is 2.

As indicated above, a compound of formula (I), and the pharmaceutically acceptable salts thereof, may exist in one of several tautomeric forms, all of which are encompassed by the present invention as individual tautomeric forms or as mixtures thereof. The compounds of formula (I) may contain at least one chiral carbon, and hence they may exist in one or more stereoisomeric forms. For example, when A^3 represents a moiety of formula $-(CH_2)_m-CH(OR^1)-$ the $CH(OR^1)$ -carbon atom is a chiral carbon. In addition, when A^3 represents a moiety of formula

-(CH₂)_{m-1}-CH=C(OR¹)- the compounds of formula (I) exist as geometric isomers. The present invention encompasses all of the isomeric forms of the compounds of formula (I) and the pharmaceutically acceptable salts thereof, whether as individual isomers or as mixtures of isomers, including racemates.

5 Suitable substituents for any heterocyclyl group include up to 4 substituents selected from the group consisting of: alkyl, alkoxy, aryl and halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, preferably a phenylene group, and wherein the carbon atoms of the aryl group represented by the said
10 two substituents may themselves be substituted or unsubstituted.

 When used herein, unless otherwise stated, the term 'aryl' includes phenyl and naphthyl; any aryl group mentioned herein may be optionally substituted with up to five, preferably up to three, groups selected from halogen, alkyl, phenyl, alkoxy, haloalkyl, hydroxy, amino, nitro, carboxy, alkoxycarbonyl,
15 alkoxycarbonylalkyl, alkylcarbonyloxy, or alkylcarbonyl groups.

 When used herein the term 'halogen' refers to fluorine, chlorine, bromine and iodine; preferably chlorine.

 As used herein, alkyl groups, whether present alone or as part of other groups such as alkoxy or aralkyl groups, are alkyl groups having straight or
20 branched carbon chains, containing up to 12 carbon atoms. Thus, suitable alkyl groups are C₁₋₁₂ alkyl groups, especially C₁₋₆ alkyl groups e.g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl or tert-butyl groups.

 Suitable substituents for any alkyl group include those indicated above in relation to the term "aryl".

25 Favoured aralkyl groups are phenylalkyl groups, optionally substituted on the aryl or alkyl moieties as defined herein.

 Suitable acyl groups include alkylcarbonyl groups

 Suitable pharmaceutically acceptable salts include salts of carboxy groups and acid addition salts.

30 Suitable pharmaceutically acceptable salts of carboxy groups include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower
35 alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine,


cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl- β -phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine, quinine or quinoline.

5 Suitable acid addition salts include pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methane-sulphonate, α -keto glutarate and α -glycerophosphate.

10 Suitable pharmaceutically acceptable solvates include hydrates.

The salts and/or solvates of the compounds of formula (I) may be prepared and isolated according to conventional procedures for example sodium salts may be prepared by using sodium methoxide in methanol.

15 In a further aspect the present invention also provides a process for the preparation of a compound of formula (I), or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, which process comprises reacting a compound of formula (II):



20

(II)

wherein A^2 and Y are as defined in relation to formula (I);

$A^{3'}$ represents a moiety of formula $-(CH_2)_m-CH(OR^{1'})-$ wherein $R^{1'}$ represents

25 R^1 as defined in relation to formula (I) or a protected form thereof, and m is as defined in relation to formula (I), or A^3 represents a moiety of formula

$-(CH_2)_{m-1}-CH=C(OR^{1'})-$ wherein $R^{1'}$ is as defined above;

$R^{2'}$ represents R^2 as defined in relation to formula (I) or a protected form thereof and R^a is a moiety convertible to a moiety of formula (f):

30



wherein A^1 , X and n are as defined in relation to formula (I);


with an appropriate reagent capable of converting R^a to the said moiety (f) and thereafter, if required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) to a further compound of formula (I);
- 5 (ii) removing any necessary protecting group;
- (iii) preparing a pharmaceutically acceptable salt of the compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.

Suitably, R^a represents $HX-(CH_2)_n-O-$ wherein X and n are as defined in relation to formula (I), or R^a represents OH.

10 Preferably, R^a represents OH.

When R^a is $HX-(CH_2)_n-O-$, an appropriate reagent capable of converting R^a to a moiety (f) is a compound of formula (III):




wherein A^1 is as defined in relation to formula (I) and R^x represents a leaving group.

A suitable leaving group R^x includes a halogen atom, preferably a chlorine or bromine atom, or a thioalkyl group for example a thiomethyl group.

20 Generally, $R^{1'}$ is R^1 . Preferably, $R^{2'}$ represents $OR^{3'}$ wherein $R^{3'}$ represents hydrogen, alkyl, aryl, aralkyl or $R^{2'}$ represents the above defined moiety $-NR^4R^5$.

When R^a is OH, an appropriate reagent is a compound of formula (IIIA):




wherein A^1 , X and n are as defined in relation to formula (I) and R^y represents a leaving group, such as a tosylate or mesylate group.

30 The reaction between the compound of formula (II) and the appropriate reagent may be carried out under conditions suitable to the particular compound of formula (II) and the reagent chosen: For example the abovementioned reaction between a compound of formula (II) wherein R^a represents $HX-(CH_2)_n-O-$ and the compound of formula (III), may be carried out in any suitable solvent, for
35 example dimethylformamide, at a temperature which provides a suitable rate of

formation of the compound of formula (I), for example at an elevated temperature in the range from 50°C to 120°C, preferably in the presence of a base such as triethylamine.

In a further example, the reaction between the compound of formula (II) wherein R^a is OH and the reagent of the abovedefined formula (IIIA) may be carried out in an aprotic solvent, such as dimethylformamide, at a low to an elevated temperature, for example in the range from 50°C to 120°C, for example at 80°C, and preferably in the presence of a base, such as sodium hydride. In an alternative aspect, when R^y in the compound of formula (IIIA) represents H and R^a is OH in the compound of formula (II), then a suitable reagent is provided by diethylazodicarboxylate and triphenylphosphine; the coupling reaction may be carried out in any suitable solvent at a low to medium temperature, for example in tetrahydrofuran at a temperature in the range of between 0 and 60°C.

A compound of formula (II), wherein A^{3'} represents a moiety of formula -(CH₂)_m-CH(OR^{1'})-, may be prepared by reacting a source of a carbene of formula (IV):



(IV)

wherein A², Y and m are as defined in relation to the compound of formula (I), R^b is a moiety R^a or a moiety convertible to a moiety R^a and R⁹ is the above defined R^{2'} or a protecting group, with a compound of formula (V):

25




(V)

wherein R^{1'} is defined in relation to formula (II); and thereafter, if required, converting a moiety R^b into a moiety R^a and removing any protecting group.

Preferably, Y is CO. Preferably, R⁹ is OR^{3'} or -NR^{4'}R⁵.

A suitable source of the carbene of formula (IV) is provided by reacting a compound of formula (IVA):




(IVA)

wherein A^2 , R^9 , R^b , Y and m are as defined in relation to formula (IV), with a
 5 suitable catalyst such as a rhodium (II) salt, for example rhodium (II) acetate, or a
 copper(II) salt, such as $\text{Cu}(\text{Cl})_2$, or copper powder.

The conditions used in the preparation of the carbene of formula (IV)
 from (IVA) will of course depend upon the particular carbene chosen, but in
 general conventional procedures are used, for example when (IV) is the carbene
 10 and (IVA) is the source of carbene then suitable conditions are analogous to those
 disclosed in Tetrahedron Lett. 1973, 2233.

The reaction between the carbene of formula (IV) and the compound of
 formula (V) may be carried out under conventional conditions, generally in an
 inert solvent, such as benzene, or when practicable in compound (V) as solvent, at
 15 any temperature providing a convenient rate of formation of the required product,
 generally at an elevated temperature, such as the reflux temperature of the
 solvent: Suitably, the conditions used are analogous to those disclosed in
 Tetrahedron Lett., 1973, 2233.

When the source of the carbene is a compound of formula (IVA), the
 20 compound of formula (IVA) may be prepared by diazotizing a compound of
 formula (VI):



25 (VI)

wherein A^2 , R^9 , R^b , Y and m are as defined in relation to the compound of
 formula (IV), with an appropriate diazotizing agent; and thereafter, if required,
 converting a moiety R^b into a moiety R^a and removing any protecting group.

30 A suitable diazotizing agent is an alkyl nitrite, such as iso-amyl nitrite.

Suitable diazotising conditions for preparing the compound of formula (IVA) are conventional conditions, for example those disclosed in Tetrahedron Lett., 1971, 4495.

Any moiety R^b may be converted into a moiety R^a by the appropriate conventional means, for example when R^b represents -OH and R^a represents $HX-(CH_2)_n-O-$ the appropriate conversion may be carried out by coupling a compound of formula (VI) wherein R^b is OH with a compound of formula (g):



wherein X and n are as defined in relation to formula (I) and R^Z is a protecting group and thereafter, if necessary, removing any protecting group.

The last abovementioned reaction is generally carried out in the presence of a suitable coupling agent; a suitable coupling agent being diethylazodicarboxylate and triphenylphosphine. The coupling reaction may be carried out in any suitable solvent at a low to medium temperature, for example in tetrahydrofuran at a temperature in the range of between 0 and 60°C.


Generally, for the preparation of compounds of formula (II), wherein R^a is OH, from compounds of formula (IV), R^b in (IV) is either OH or a suitably protected OH, such as a silylated OH.

The compounds of formula (V) are known commercially available compounds or they may be prepared using methods analogous to those used to prepare such compounds.

The compounds of formula (VI) are known compounds or they may be prepared using methods analogous to those used to prepare known compounds, for example those disclosed in Tetrahedron Lett., 1971, 4495, in particular the compound wherein R^9 is OCH_3 , m is 1, A^2 is 1,4-phenylene and R^b is OH is a commercially available compound.

The compounds of formula (g) are known compounds or they may be prepared using methods analogous to those used to prepare known compounds, for example those disclosed in EP0356214.

A compound of formula (I), wherein A^3 represents a moiety of formula $-(CH_2)_m-CH(OR^1)-$, or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may also be prepared by reacting an activated form of a compound of formula (VII):



5 (VII)

wherein A^1 , A^2 , X, Y, m and n are as defined in relation to formula (II) and R^9 is as defined in relation to formula (IV) with a compound of formula (VIII);

10 $R^1 - L^1$ (VIII)

wherein R^1 is as defined in relation to formula (I) and L^1 represents a leaving group or atom; and thereafter if required carrying out one or more of the following optional steps:

- 15
- (i) converting a compound of formula (I) into a further compound of formula (I);
 - (ii) removing any protecting group; and
 - (iii) preparing a pharmaceutically acceptable salt of a compound of formula (I)
- 20 and/or a pharmaceutically acceptable solvate thereof.

Suitably, L^1 is a halogen atom, for example a bromine atom.

A suitable activated form of a compound of formula (VII) is an anionic form such as a salted form and especially an alkali metal salted form, for example a sodium salt.

25 The activated form of the compound of formula (VII) may be prepared by any appropriate conventional procedure. For example, the anionic form of the compound of formula (VII) may be prepared by treating the compound of formula (VII) with a base, such as a metal hydride base, for example sodium hydride.


30 The reaction conditions for the reaction between the compounds of formulae (VII) and (VIII) are generally conventional alkylation conditions. For example the reaction between the salted form of a compound of formula (VII) and a compound of formula (VIII) may be carried out in an aprotic solvent, such

as dimethylformamide, at any temperature providing a suitable rate of formation of the required product, generally an elevated temperature such as in the range of 40°C to 100°C, for example 80°C.

5 Favourably, the formation of the activated form of (VII) from (VII) - for example the formation of a salted form of (VII) - may be carried out *in-situ* prior to the reaction of the activated form of (VII) with the above defined compound of formula (VIII).

A compound of formula (VII) may be prepared by reacting a compound of formula (IX):

10



(IX)

15 wherein R^a , R^9 , A^2 , Y and m are as defined above and T^1 is hydrogen or a hydroxyl protecting group, with an appropriate reagent capable of converting R^a to a moiety of the above defined formula (I).

The reagent capable of converting R^a to a moiety of formula (f) is as defined above in relation to the formation of a compound of formula (I) from a compound of formula (II).

20 Suitable values for R^a include those described hereinbefore.


Suitable reaction conditions for the reaction of the compound of formula (IX) and the appropriate reagent include those described above in relation to the preparation of compound (II) with the said appropriate reagent.

25 Preferably, in the compound of formula (IX), R^a represents a hydroxyl group and a particularly appropriate reagent is the above defined compound of formula (IIIA).

30 The reaction between the compound of formula (IX), wherein R^a is an hydroxyl group, and the reagent of the abovedefined formula (IIIA) may be carried out in an aprotic solvent, such as dimethylformamide, at a low to an elevated temperature, for example in the range of from 50°C to 120°C, for example at 80°C, and preferably in the presence of a base, such as sodium hydride.

The compounds of formula (IX), wherein R^a is OH, are known compounds or they are compounds prepared by methods analogous to those used to prepare known compounds, for example those disclosed in Dictionary of Organic Compounds 5th Edition, Vol. 3, p.3222, Chapman & Hall, or D.H. Williams *et. al.* J.Chem.Soc., Section B, 1969, 439, or J. March, Advanced Organic Chemistry, 3rd Edition (1985), Wiley Interscience or for example those disclosed in International Application, Publication No. WO92/02520.

A compound of formula (I), wherein A³ represents a moiety of formula - (CH₂)_m-CH(OR¹)-, or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may also be prepared by reacting a source of a carbene of formula (X):




(X)

wherein A¹, A², X, Y, m and n are as defined in relation to formula (I) and R⁹ is as defined in relation to formula (IV), with a compound of the above defined formula (V); and thereafter, if required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) into a further compound of formula (I);
- (ii) removing any protecting group; and
- (iii) preparing a pharmaceutically acceptable salt of a compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.

A suitable source of a carbene of formula (X) is provided by reacting a compound of formula (XI):



(XI)


wherein A^1 , A^2 , R^9 , X , Y , m and n are as defined in relation to formula (X) with a suitable catalyst such as a rhodium (II) salt, for example rhodium (II) acetate, or a copper(II) salt, such as $Cu(Cl)_2$, or copper powder.

The carbene of formula (X) may be prepared from the compound of formula (XI) by using an analogous procedure to that used for the preparation of the carbene of formula (IV) from the compound of formula (IVA).

The reaction conditions for the reaction between the compounds of formulae (X) and (V) are equivalent to those used in the reaction between the compounds of formulae (IV) and (V).

The compound of formula (XI) may be prepared by reaction between the compounds of formulae (IIIA) and (VI) using an analogous procedure to that used for the preparation of the compound of formula (I) from the compounds of formulae (II) and (IIIA) and thereafter diazotized as described above for the conversion of (VI) to (IVA).

A compound of formula (I) wherein A^3 represents a moiety of formula $-(CH_2)_{m-1}-CH=C(OR^1)-$ or $-(CH_2)_m-CH(OR^1)-$, or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may also be prepared by reacting a compound of formula (XII):




wherein A^1 , A^2 , X , m and n are as defined in relation to formula (I), with a reagent capable of converting the CHO carbon atom into a group of the above defined formula $CH=C(OR^1)-Y.R^2$; and thereafter, if required, reducing the group $-CH=C(OR^1)-$ to provide a compound wherein A^3 represents a moiety of formula $-(CH_2)_m-CHOR^1-$ and thereafter, if required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) into a further compound of formula (I);
- (ii) removing any protecting group; and

- (ii) preparing a pharmaceutically acceptable salt of a compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.

A suitable reagent capable of converting the CHO carbon atom into a group of the above defined formula $-\text{CH}=\text{C}(\text{OR}^1)-\text{Y}.\text{R}^2$ is a Wittig reagent or preferably a Wadsworth Emmons reagent of formula (XIII):



(XIII)


- wherein R^1 , R^2 and Y are as defined in relation to formula (II) and R^{10} represents a C_{1-6} alkyl group, preferably a methyl or ethyl group.

The reaction between the compounds of formulae (XII) and (XIII) may be carried out under conventional Wadsworth Emmons reaction conditions, for example in an aprotic solvent, such as tetrahydrofuran, at low to ambient temperature, such as in the range of from 0° to 25°C , conveniently at ambient temperature, preferably in an inert atmosphere and under anhydrous conditions. Preferably the compound of formula (XIII) is suitably activated, for example by the addition of a base such as sodium hydride or n-butyl lithium, prior to the addition of the compound of formula (XII).

- The reduction of a compound wherein A^3 represents a moiety of formula $-(\text{CH}_2)_{m-1}-\text{CH}=\text{C}(\text{OR}^1)-$ to provide a compound wherein A^3 represents a moiety of formula $-(\text{CH}_2)_m-\text{CH}(\text{OR}^1)-$ may be carried out using conventional reduction methods, such as catalytic reduction using for example a 10% palladium-on-carbon catalyst in an alkanolic solvent such as ethanol, or by use of a metal/solvent system such as magnesium metal/methanol as described in Tet. Lett. 1986, 27, 2409.

A compound of formula (XII) may be prepared from a compound of formula


(XIIA):



(XIIA)

wherein A^1 , A^2 , X, m and n are as defined in relation to formula (I) and R^c represents hydrogen or a C_{1-6} alkyl group, suitably a methyl group, by conventional methods for converting an ester group into a carbonyl group; one convenient method involves reducing the ester group to give a primary alcohol
 5 using for example a metal hydride reducing agent such as lithium aluminium hydride in tetrahydrofuran, and thereafter oxidising the primary alcohol to give the required carbonyl group by use of an oxidising reagent such as pyridine-sulphur trioxide complex in dimethylsulphoxide.

A compound of formula (XIIA) may be prepared from a compound of
 10 formula (XIIB):




(XIIB)

wherein A^2 , m and R^c are as defined in relation to formula (XIIA), with a
 15 compound of the above defined formula (IIIA).

Suitably reaction conditions for the reaction between the compounds of formulae (IIIA) and (XIIB) are those described above for the reaction between the compounds of formulae (II) and (IIIA).

A compound of formula (II) wherein $A^{3'}$ represents a moiety of formula
 20 $-CH=C(OR^{1'})-$ or $-CH_2-CH(OR^{1'})-$, or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be prepared by reacting a compound of formula (XIV):



(XIV)

wherein R^b and A^2 are as defined in relation to formula (IV), with a reagent capable of converting the CHO carbon atom into a group of the above defined formula $-CH=C(OR^{1'})-Y.R^{2'}$; and thereafter, if required, reducing the group -
 30 $CH=C(OR^{1'})-$ to provide a group of formula $-CH_2-CHOR^{1'}$; and thereafter, if required, removing any protecting group.

Preferably, R^b is a protected OH group.

A suitable reagent capable of converting the CHO carbon atom of compound (XIV) into a group of the above defined formula

-CH=CH(OR^{1'})-Y.R^{2'} is a compound of the above defined formula (XIII) in optionally protected form as defined by the nature of R^{1'} and R^{2'} in the required compound of formula (II).

Suitable conditions for the reaction between the compound of formula (XIV) and the said reagent are analogous to those described above for the reaction between the compounds of formulae (XII) and (XIII).


The compounds of formula (XII), in particular those wherein m is 1, may also be prepared by methods disclosed in EP0306228.

The compounds of formula (XIIB) are known commercially available compounds or they are compounds prepared by analogous methods used to prepare such compounds or they may be prepared from such compounds, for example by converting a commercially available carboxylic acid into an alkyl ester.

The compounds of formula (XIII), are known compounds or they are compounds prepared by methods analogous to those used to prepare known compounds, for example those disclosed in Annalen Chemie 1966, 699, 53 or J. Org. Chem. 1983, 48, 3408 and Tetrahedron 1992, 48, 3991.

The compounds of formulae (XIV) are known compounds or they are compounds prepared by methods analogous to those used to prepare known compounds, for example those disclosed in EP 0306228.

A compound of formula (I), wherein A³ represents a moiety of formula -CH₂ - CH(OR¹)- wherein R¹ represents alkyl, or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may also be prepared by hydrolysing a compound of formula (XV):



(XV)


wherein A¹, A², R¹, X and n are as defined in relation to formula (I) to provide a compound of formula (I) wherein R² represents OH; and thereafter, if required, converting R² as OH into another R²; and thereafter, if required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) into a further compound of formula (I);
 (ii) removing any protecting group; and
 (iii) preparing a pharmaceutically acceptable salt of a compound of formula (I)
 5 and/or a pharmaceutically acceptable solvate thereof.

The hydrolysis of the compound of formula (XV) may be carried out using conventional conditions and reagents for nitrile hydrolysis, for example basic hydrolysis using 10% sodium hydroxide in methanol.

The conversion of R² as OH into another R² may be effected by using
 10 any convenient method, such as those methods described hereinafter.


A compound of formula (XV) may be prepared from a compound of formula (XVI):




wherein A¹, A², X and n are as defined in relation to formula (I) and R^{1a} = R^{1b} which represents alkyl; by reaction with trimethylsilylcyanide.

20 The reaction between the compounds of formulae (XVI) and trimethylsilylcyanide may be carried out in an inert solvent, such as dichloromethane, at low to ambient temperature, conveniently at ambient temperature and preferably in the presence of a Lewis acid catalyst, such as boron trifluoride etherate.

25 A compound of formula (XVI) may be prepared from a compound of formula (XVII):



wherein A¹, A², R^{1a}, X and n are as defined in relation to formula (XV); by reaction with a compound of formula (XVIII):




wherein R^{1a} is as defined above.

The reaction between the compounds of formulae (XVII) and (XVIII) is suitably carried out using the compound of formula (XVIII) as solvent, generally at an elevated temperature such as the reflux temperature of the solvent and preferably in the presence of p-toluenesulphonic acid.

5 Preferably, R^{1a} is methyl.

A compound of formula (XVII) may be prepared by reaction of the above defined compound of formula (XII), wherein m is 1, with a reagent capable of converting the CHO carbon atom of formula (XII) into a group of the above defined formula -CH=CH - OR¹, the reagent being suitably a Wittig reagent of
10 formula (XIX):



(XIX)

wherein R¹ is as defined in relation to formula (I).

15 The reaction between the compounds of formulae (XII) and (XIX) may be carried out under conventional Wittig reaction conditions, for example in an aprotic solvent, such as tetrahydrofuran, at low to ambient temperature, such as in the range of from -10° to 25°C, conveniently at ambient temperature and, preferably, in an inert atmosphere under anhydrous conditions. Preferably, the
20 compound of formula (XIX) is suitably activated by, for example, the addition of a base such as sodium hydride, n-butyl lithium or lithium diisopropylamide, prior to the addition of the compound of formula (XII).

The compounds of formula (XVIII) and (XIX) are known compounds or they are compounds prepared by methods analogous to those used to prepare
25 known compounds, for example those disclosed in J. March, Advanced Organic Chemistry, 3rd Edition (1985), Wiley Interscience.

A compound of formula (I), wherein A³ is (CH₂)_m-CH(OR¹)- and R² is a C-linked aromatic heterocyclyl group, or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable
30 solvate thereof, may be prepared by reacting a compound of the above defined formula (XII) with an activated form of a compound of formula (XX)



(XX)


wherein het-CH is an aromatic heterocyclic group represented by R^2 which contains at least 1 carbon atom and thereafter converting the compound wherein R^1 is hydrogen into another R^1 ; and thereafter if required:

- (i) converting a compound of formula (I) to a further compound of formula (I);
- (ii) removing any necessary protecting group;
- (iii) preparing a pharmaceutically acceptable salt of the compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.

A suitable activated form of a compound of formula (XX) is a salted form such as a lithium salted form.

The activated form of a compound of formula (XX) may be prepared by reacting an aromatic heterocyclic group Het-CH or Het-CL, wherein L is a leaving group such as halogen, with an appropriate, conventional activating agent such as a salting agent, for example an alkyl lithium, in an aprotic solvent such as tetrahydrofuran according to known methods and procedures for example those disclosed in Adv. Heterocyclic chem., 1993, 56, 155.

Compounds of formula (I) wherein A^3 is $(CH_2)_m-CH(OR^1)-$ and R^2 is a C-linked tetrazolyl group or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein the heterocyclyl group may be prepared by reacting a compound of formula (XXI)



(XXI)

wherein A^1 , A^2 , R^1 , X, m and n are as defined in relation to formula (I), with a source of azide ions such as an azide salt, suitably an alkali metal azide, for example sodium azide.

The compound of formula (XXI) may be prepared by dehydrating a compound of formula (I) wherein A^3 is $(CH_2)_m-CH(OR^1)$ and YR^2 is $CONH_2$ using for example $POCl_3$.

The reaction between the compound of formula (XXI) and the source of azide ions may be carried out under conventional conditions for example when sodium azide is the source of azide ions the reaction may be effected in an aprotic solvent such as dimethylformamide generally at an elevated temperature, for example the reflux temperature of the solvent; preferably in the presence of trimethylsilyl chloride.

The abovementioned conversion of a compound of formula (I) into a further compound of formula (I) includes:

- a) converting one group R into another group R ;
- b) converting one group OR^1 into another group OR^1 ;
- c) converting one group $Y.R^2$ wherein Y is CO into another group $Y.R^2$;
- d) converting one group $CO.R^2$ into another group $CS.R^2$; and
- e) reducing a group $-CH=C(OR^1)-$ to a group $-CH_2-CH(OR^1)-$.

The abovementioned conversions may as appropriate be carried out on any of the intermediate compounds mentioned herein.

The conversion of a compound of formula (I) to a further compound of formula (I) may be carried out by using any appropriate conventional procedure.

Suitable conversions of one group R into another group R include converting a group R which represents hydrogen into a group R which represents an acyl group; such conversion may be carried out using an appropriate conventional acylation procedure, for example treating an appropriately protected compound of formula (I) with an acylating agent. Thus acetic anhydride may be used to prepare the compound of formula (I) wherein R is acetyl.

The above mentioned reduction may be carried out using any conventional reduction method, for example using borohydride reducing agents, such as sodium borohydride in a solvent such as methanol.

Suitable conversions of one group $Y.R^2$ wherein Y is CO into another group $Y.R^2$, include:

- (i) hydrolysing one group $Y.OR^{3a}$ wherein R^{3a} is alkyl, aryl or aralkyl into a group $Y.OH$, wherein Y is CO;
- (ii) aminating one group $Y.R^{2b}$ wherein R^{2b} is alkoxy into a group $Y.NR^4R^5$, wherein Y is CO;

(iii) halogenating the above defined group Y.OH to provide the corresponding acid halide, and then aminating the halide to provide the abovementioned group Y.NR⁴R⁵ wherein Y is CO;

(iv) esterifying a group YOH to give a group Y-Oalkyl or Y-Oaralkyl,

5 wherein Y is CO; and

(v) converting one group Y.NH₂ wherein Y is CO into a group Y-C-Het wherein Y is a bond and C-Het is a C-linked aromatic heterocyclyl group.

Suitable hydrolysis methods for use in conversion c(i) are conventional ester hydrolysis methods, for example using an alkali hydroxide in aqueous
10 methanol.

Suitable amination methods for conversion c(ii) or c(iii) include conventional methods, for example treatment with aqueous ammonia in tetrahydrofuran/methanol.

Suitable halogenation methods for conversion c(iii) include conventional
15 methods, for example treatment with oxalyl chloride.

Suitable esterification methods for conversion c(iv) are conventional methods, thus alkyl esters may be prepared by using the appropriate alkanol, for example methanol, in the presence of an acid and aralkyl esters may be prepared by treatment of a salted YOH group, such as a sodium salt, with an appropriate
20 aralkyl halide, for example benzyl bromide.

Suitable conversion of a group Y.NH₂ wherein Y is CO into a group Y-C-Het wherein Y is a bond and C-Het is a C-linked aromatic heterocyclyl group includes:

- a) reaction with a hydrazine, for example hydrazine hydrate, and an amide acetal,
25 such as dimethylformamide dimethyl acetal, to provide a 1,2,4-triazole; or
- b) reaction with a hydroxylamine, for example hydroxylamine hydrochloride, and an amide acetal, such as dimethylformamide dimethyl acetal, to provide a 1,2,4-oxadiazole.

Suitable conversions of one group CO.R² into another group CS.R² may
30 be effected using conventional methods, for example by using Lawesson's reagent in a solvent such as toluene, at any temperature providing an acceptable rate of formation of the required product, conveniently at the reflux temperature of the solvent.

Suitable reductions of one group -CH=C(OR¹)- to a group -
35 CH₂CH(OR¹)- may be carried out using any convenient reduction procedure,

such as the catalytic reduction or metal/solvent reduction methods as described hereinbefore.

It will be appreciated that in any of the abovementioned reaction including the abovementioned conversions (a), (b), (c), (d) and (e) any reactive group in the substrate molecule may be protected, according to conventional chemical practice.


Suitable protecting groups in any of the abovementioned reactions are those used conventionally in the art. Thus, for example, suitable hydroxyl protecting groups include benzyl or trialkylsilyl groups.

The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected. Thus for example a benzyloxy group may be prepared by treatment of the appropriate compound with a benzyl halide, such as benzyl bromide, and thereafter, if required, the benzyl group may be conveniently removed using catalytic hydrogenation or a mild ether cleavage reagent such as trimethylsilyl iodide or boron tribromide.

Where appropriate the isomeric forms of the compounds of formula (I) and the pharmaceutically acceptable salts thereof may be prepared as individual isomers using conventional chemical procedures.

However for certain compounds of formula (I) there is provided a novel process for separating optical isomers of such compounds. Indeed the newly discovered process is considered to be capable of separating optical isomers of any compound providing the chiral carbon of such compound is attached to a carboxy ester group and a group OZ^1 wherein Z^1 is alkyl, aryl or aralkyl.

Accordingly, the present invention provides a process for separating optical isomers of a compound (the substrate ester) which comprises a moiety of formula (H):



(H)

wherein C^* is a chiral carbon, Z is a C_{1-12} alkyl group and Z^1 is a C_{1-12} alkyl, aryl or an aryl C_{1-12} alkyl group,

which process comprises enantioselectively hydrolysing the ester group CO_2Z of one enantiomer into a carboxyl group with a lipase from *Rhizopus delemar*, *Rhizopus arrhizus*, *Rhizopus LIP F4* or a lipase from *Mucor miehei*; and thereafter, as necessary, isolating either the enantiomerically enriched product
5 carboxylic acid or the enantiomerically enriched substrate ester.

The enantiomerically enriched product carboxylic acid and/or the enantiomerically enriched substrate ester may be isolated using conventional extraction methods, such as phase separation and/or extraction into a suitable solvent, and thereafter, if required it may be chromatographed.

10 In an alternative isolation procedure, prior to isolation, the enantiomerically enriched substrate ester, may be converted by hydrolysis into the respective carboxylic acid which may then be isolated in the usual way. In one convenient aspect of the invention the enantiomerically enriched substrate ester may be hydrolysed by treatment with the abovementioned lipases to give the
15 respective carboxylic acid.

The compounds of formula (I) which fall within formula (H) are those compounds wherein Z represents R^3 and Z^1 represents R^1 : Thus the novel process may be used to prepare enantiomerically enriched compounds of formula (I) wherein A^3 represents $(\text{CH}_2)_m\text{-CH}(\text{OR}^1)\text{-}$, Y represents CO, R^2 is OR^3 and
20 A^1 , A^2 , R^1 , R^3 X, m and n are as defined in relation to formula (I)- (hereinafter referred to as compounds of formula (IA)).

The microbial lipase enzymes may be obtained by conventional culturing techniques such as those disclosed in J. Bacteriol., 1982, Vol.150 498-505. H. Gilbert and M. Tully, European Patent Application No. 0198440 and British
25 Patent No. 1,474,519. The lipase may be isolated as a pure enzyme or, in the alternative a suitable source of the lipase may be incorporated into the reaction.

Preferably, the microbial lipase enzymes are obtained commercially as purified or partially purified enzyme preparations.

30 The hydrolysis of the compound of formula (H) may be carried out in any suitable aqueous solvent having controlled pH, for example in an aqueous buffer or in a solvent wherein the pH is controlled by the addition of aqueous sodium hydroxide, at a pH which provides a suitable rate of formation of the required product, which is generally a pH in the range of from 5 to 9, such as in the range of from 6 to 8, for example at pH7.

The hydrolysis may be carried out at any temperature which provides a suitable rate of formation of the required product, being generally at a low to ambient temperature, such as a temperature in the range of from 5°C to 40°C, such as in the range of from 20°C to 40°C and preferably in the range of from 20°C to 30°C, for example 23°C.

Generally, the substrate mixture is introduced into the reaction system as a solution in an organic solvent which may be a water miscible solvent such as acetone, tetrahydrofuran, dimethylsulphoxide, dimethylformamide or acetonitrile.

The stereoselective process selectively hydrolyses the compound (IA) having the same stereochemistry at the asterisked carbon atom as the equivalent carbon atom in (-) 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-methoxypropanoic acid.

The reaction conditions, such as the particular acidic pH and the reaction temperature which provide optimum enrichment for any particular enantiomerically enriched compound (H) may be determined by routine experimentation.

Suitably, the stereoselective reaction provides enantiomerically enriched compound (IA) in the form wherein the required enantiomer is present in greater than 70% w/w; and favourably greater than 80% w/w. Most favourably, the product from the stereoselective process provides enantiomerically enriched compound (IA) in the form wherein the required enantiomer is present as 80-100% w/w, preferably 90-100%, such as 90-95%, and most preferably 95-100%, for example 95%, 96%, 97%, 98%, 99% or 100% w/w.

The above mentioned enantiomerically enriched compound (IA) is considered to form a further aspect of the present invention. Accordingly the present invention provides enantiomerically enriched compound (IA) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof.

The present invention also provides enantiomerically enriched compound (IA) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein the required isomer is present in greater than 50% w/w; suitably greater than 70% w/w and favourably greater than 80% w/w. Most favourably, the enantiomerically enriched compound (IA) is in a form wherein 80-100% w/w, preferably 90-100%, such as 90-95%, and most preferably 95-100%, for example 95%, 96%,

97%, 98%, 99% or 100% w/w is in the form of the required isomer of a compound of formula (IA).

In one preferred aspect there is provided a compound of formula (IA) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a
5 pharmaceutically acceptable solvate thereof, preferably in optically pure form.

The absolute stereochemistry of compounds may be determined using conventional methods, such as X-ray crystallography.

As mentioned above the compounds of the invention are indicated as having useful therapeutic properties: The present invention accordingly provides
10 a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use as an active therapeutic substance.

Thus the present invention provides a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a
15 pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of hyperglycaemia.

In a further aspect the present invention also provides a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the
20 treatment and/or prophylaxis of hyperlipidaemia.

As indicated hereinbefore the present invention also provides a compound of formula (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof for use in the
25 treatment of hypertension, cardiovascular disease and certain eating disorders.

Cardiovascular disease includes in particular atherosclerosis.

Certain eating disorders include in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating, such as anorexia nervosa, and disorders associated with over-eating, such as obesity and anorexia bulimia.

30 A compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.

Accordingly, the present invention also provides a pharmaceutical
35 composition comprising a compound of the general formula (I), or a tautomeric

form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.

As used herein the term 'pharmaceutically acceptable' embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.

The composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.

Usually the pharmaceutical compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.

Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. Other fixed unit dosage forms, such as powders presented in sachets, may also be used.

In accordance with conventional pharmaceutical practice the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant or other conventional adjuvant.

Typical carriers include, for example, microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate or sodium lauryl sulphate.

Most suitably the composition will be formulated in unit dose form. Such unit dose will normally contain an amount of the active ingredient in the range of from 0.1 to 1000 mg, more usually 0.1 to 500 mg, and more especially 0.1 to 250 mg.

The present invention further provides a method for the treatment and/or prophylaxis of hyperglycaemia in a human or non-human mammal which comprises administering an effective, non-toxic, amount of a compound of the general formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof to a hyperglycaemic human or non-human mammal in need thereof.

The present invention further provides a method for the treatment of hyperlipidaemia in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a

pharmaceutically acceptable solvate thereof, to a hyperlipidaemic human or non-human mammal in need thereof.

Conveniently, the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular
5 aspect of the present invention.

In the treatment and/or prophylaxis of hyperglycaemic humans, and/or the treatment and/or prophylaxis of hyperlipidaemic human, the compound of the general formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may
10 be taken in doses, such as those described above, one to six times a day in a manner such that the total daily dose for a 70 kg adult will generally be in the range of from 0.1 to 6000 mg, and more usually about 1 to 1500 mg.

In the treatment and/or prophylaxis of hyperglycaemic non-human mammals, especially dogs, the active ingredient may be administered by mouth,
15 usually once or twice a day and in an amount in the range of from about 0.025 mg/kg to 25 mg/kg, for example 0.1 mg/kg to 20 mg/kg. Similar dosage regimens are suitable for the treatment and/or prophylaxis of hyperlipidaemia in non-human mammals.

The dosages regimens for the treatment of hypertension, cardiovascular
20 disease and eating disorders will generally be those mentioned above in relation to hyperglycaemia.

In a further aspect the present invention provides the use of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for the
25 manufacture of a medicament for the treatment and/or prophylaxis of hyperglycaemia.


The present invention also provides the use of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a
30 medicament for the treatment and/or prophylaxis of hyperlipidaemia, hypertension, cardiovascular disease or certain eating disorders.

No toxicological effects have been established for the compounds of formula (I) in the abovementioned dosage ranges.

The following Procedures and Examples illustrate the invention but do not
35 limit it in any way.

Example 1

Ethyl (E/Z)-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-phenoxyethoxy)propenoate



A solution of triethyl 2-(2-phenoxyethoxy)phosphonoacetate (4.86 g) in dry tetrahydrofuran (50 mL) was added slowly to a stirred, ice-cooled suspension of sodium hydride (60% dispersion in oil; 0.60 g) in dry tetrahydrofuran (25 mL) under an argon atmosphere. The mixture was stirred at 0°C for 30 minutes prior to the addition of a solution of 4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]benzaldehyde (*Eur. Patent Appl., Publication No. 0306228*) (4.00 g) in dry tetrahydrofuran (50 mL). The mixture was allowed to warm to room temperature and stirred for a further 22 hrs. The solvent was evaporated and the residue suspended in water (700 mL) and extracted with ethyl acetate (3x500 mL). The combined ethyl acetate layers were washed with water (1L), brine (500 mL), dried (MgSO₄) and evaporated. The residue was chromatographed on silica gel with 2% ethyl acetate in dichloromethane as eluent to afford the title compound, a gum, as a mixture of double bond isomers which were only partially separated by chromatography. These were recombined to afford a 71:29 Z:E mixture, used directly in the next stage. [Found C, 69.3; H, 6.05; N, 5.7%; M⁺ (EI) 502.2103. Calculated for C₂₉H₃₀N₂O₆ C, 69.3; H, 6.0; N, 5.6%; M⁺ 502.2104].

¹H NMR δ (CDCl₃)

Z-Isomer: 1.35 (3H, t); 3.34 (3H, s); 3.95 (2H, t); 4.30 (8H, complex); 6.79-7.40 (12H, complex) and 7.79 (2H, d).


E-Isomer: 1.13 (3H, t); 3.34 (3H, s); 3.95 (2H, t); 4.10-4.40 (8H, complex); 6.23 (1H, s) and 6.70-7.40 (13H, complex).

The assignment of the major isomer as Z is by analogy with reported chemical shifts of similar olefinic protons (cf R. A. Aitken and G. L. Thom, *Synthesis*, 1989, 958).

Example 2

Methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-phenoxyethoxy)propanoate

5



10 Magnesium turnings (1.0 g) were added to a mixture of ethyl (E/Z)-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-phenoxyethoxy)-propanoate (4.51 g) and a crystal of iodine dissolved in methanol (150 mL) at room temperature. The mixture was stirred with slight warming until reaction ensued, at which point the heating was stopped and the mixture stirred at room temperature during the addition, over *ca* 5 minutes, of a further portion of magnesium (5.50 g). The reaction mixture was immersed in a cold water bath and stirring continued for 19 hrs then the mixture was evaporated *in vacuo*. The residue was suspended in water (500 mL) and stirred vigorously during the addition of concentrated hydrochloric acid to give (once *all* the suspension had dissolved) a final pH of 2.5. The mixture was extracted with ethyl acetate 2x500 mL) and the combined ethyl acetate layers then washed with water 20 (800 mL), brine (500 mL), dried (MgSO₄) and evaporated. The residue was chromatographed on silica gel with 2% ethyl acetate in dichloromethane as eluent to afford the title compound, a gum, which was used directly in the next stage. [Found M⁺ (EI) 490.2105. Calculated for C₂₈H₃₀N₂O₆ M⁺ 490.2104].


25 ¹H NMR δ (CDCl₃)

2.99 (2H, m); 3.34 (3H, s); 3.67 (3H, s); 3.68 (1H, m); 3.92 (3H, complex); 4.03 (2H, m); 4.20 (3H, complex) and 6.72-7.37 (13H, complex).

Example 3

3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-phenoxyethoxy)propanoic acid

5



A mixture of methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]-phenyl]-2-(2-phenoxyethoxy)propanoate (3.36 g), 10% aqueous sodium hydroxide solution (20 mL) and methanol (30 mL) was stirred for 3 hrs at room temperature, concentrated and then diluted with water (500 mL) and acidified to pH2 with concentrated hydrochloric acid. The mixture was extracted with ethyl acetate (3x400 mL) and the combined ethyl acetate solutions washed with water (1 L) and brine (500 mL), dried (MgSO₄) and evaporated to afford the title compound, a gum, which was used directly in the salt forming stage.


¹H NMR δ (CDCl₃)

2.95 (1H, dd); 3.13 (1H, dd); 3.32 (3H, s); 3.75-4.20 (9H, complex); 4.75 (1H, broad, exchanges with D₂O) and 6.70-7.40 (13H, complex).

Example 4

3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-phenoxyethoxy)propanoic acid, sodium salt

25




Sodium hydride (60% dispersion in mineral oil, 0.12 g) was added to a stirred solution of 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-phenoxyethoxy)propanoic acid (1.30 g) in methanol (20 mL). The mixture was stirred at room temperature for 1 hr, concentrated *in vacuo* and diluted with diethyl ether (50 mL). The resulting solid was filtered and dried to afford the title compound, mp 60-62°C. [Found MH⁺ of free acid (FAB) 477.2056. Calculated for free acid (M = C₂₇H₂₈N₂O₆) MH⁺ 477.2025].

¹H NMR δ (DMSO- d_6)

2.65 (1H, dd); 2.88 (1H, dd); 3.22 (3H, s); 3.46 (1H, m); 3.60 (1H, dd); 3.87
 5 (3H, complex); 3.93 (2H, m); 4.18 (2H, t) and 6.70-7.40 (13H, complex).

Example 5

10 **Ethyl (E/Z)-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-benzyloxyethoxy)propenoate**



15 The title compound, a gum, was obtained as a 72:28 mixture of Z and E double bond isomers when triethyl 2-(2-benzyloxyethoxy)phosphonoacetate was reacted with 4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]benzaldehyde in a manner similar to that described in Example 1. The double bond isomers were only partially separated by chromatography on silica gel with 2.5% ethyl acetate in dichloromethane as eluent and were recombined for use in the next stage. [Found
 20 M^+ (EI) 516.2259. Calculated for $C_{30}H_{32}N_2O_6$ M^+ 516.2260].


¹H NMR δ (CDCl₃)

25 **Z-Isomer:** 1.34 (3H, t); 3.33 (3H, s); 3.77 (2H, m); 3.93 (2H, t); 4.13 (2H, m); 4.20 (2H, t); 4.27 (2H, q); 4.53 (2H, s); 6.71 (2H, d); 6.96 (1H, s); 6.97-7.40 (9H, complex) and 7.79 (2H, d).

E-Isomer: 1.13 (3H, t); 3.34 (3H, s); 3.75-4.65 (12H, complex); 6.15 (1H, s); 6.75 (2H, d) and 6.90-7.90 (11H, complex).

Example 6

Methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-benzyloxyethoxy)propanoate




The title compound, a gum, was prepared from ethyl (E/Z)-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-benzyloxyethoxy)propanoate in a manner similar to that described for Example 2. [Found M^+ (EI) 504.2261. Calculated for $C_{29}H_{32}N_2O_6$ M^+ 504.2261].

 1H NMR δ ($CDCl_3$)

2.95 (2H, complex); 3.33 (3H, s); 3.40-3.80 (4H, complex); 3.67 (3H, s); 3.92 (2H, t); 4.10 (1H, t); 4.19 (2H, t); 4.45 (2H, s); 6.77 (2H, d) and 6.95-7.40 (11H, complex).

Example 7

3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-benzyloxyethoxy)propanoic acid



The title compound, a gum, was prepared from methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-benzyloxyethoxy)propanoate by a procedure similar to that described for Example 3. [Found MH^+ (CI) 491.2180. Calculated for $C_{28}H_{30}N_2O_6$ MH^+ 491.2182].

 1H NMR δ ($CDCl_3$)

2.95 (1H, m); 3.15 (1H, m); 3.32 (3H, s); 3.50-3.70 (4H, m); 3.90 (2H, t); 4.07 (1H, m); 4.17 (2H, t); 4.52 (2H, s); 6.50 (1H, br, exchanges with D_2O) and 6.95-7.45 (13H, complex).

DEMONSTRATION OF EFFICACY OF COMPOUNDS**Obese Mice, Oral Glucose Tolerance Test.**

5

C57bl1/6 obese (ob/ob) mice were fed on powdered oxoid diet. After at least one week, the mice continued on a powdered oxoid diet or were fed powdered oxoid diet containing the test compound. After 8 days on the supplemented diet all of the mice were fasted for 5 hours prior to receiving an oral load of glucose (3g/kg). Blood samples for glucose analysis were taken 0,45,90 and 135 minutes after glucose administration and the results appear below as the percentage reduction in area under the blood glucose curve where test compound treated groups are compared with the control group. 8 mice were used for each treatment.


15

Table

Example No.	Level in diet ($\mu\text{mol.kg}^{-1}$ of diet)	% Reduction in area under blood glucose curve
4	100	61


CLAIMS/A

1. A compound of formula (I):




- or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:
- 10 A^1 represents a substituted or unsubstituted aromatic heterocyclyl group;
 A^2 represents a benzene ring having three optional substituents;
 A^3 represents a moiety of formula $-(CH_2)_m-CH(OR^1)-$ wherein m represents an integer in the range of from 1 to 5 and R^1 represents a moiety $-(CH_2)_x-Y^1-(CH_2)_y-T$ wherein Y^1 represents O, NR° wherein R° is H, alkyl or alkylcarbonyl or Y^1 is S, T represents a phenyl group optionally substituted with up to 3 substituents selected from halo, alkyl and alkoxy, x represents an integer in the range of from 2 to 5 and y represents zero or an integer in the range of from 1 to 5; or
- 15 A^3 represents a moiety of formula $-(CH_2)_{m-1}-CH=C(OR^1)-$ wherein R^1 and m are as defined above;
- 20 R^2 represents OR^3 wherein R^3 represents hydrogen, alkyl, aryl or aralkyl or R^2 represents an aromatic heterocyclyl group or $-NR^4R^5$ wherein R^4 and R^5 each independently represent hydrogen, alkyl or alkylcarbonyl or R^4 and R^5 together with the nitrogen atom to which they are attached form a heterocyclic ring, providing that R^2 represents an aromatic heterocyclyl group only when Y as defined below represents a bond ;
- 25 X represents NR wherein R represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;
- 30 Y represents $C=O$ or $C=S$ or a bond providing that Y represents a bond only when R^2 represents the above mentioned aromatic heterocyclyl group; and n represents an integer in the range of from 2 to 6.


2. A compound according to claim 1, wherein A¹ represents a moiety of formula (a), (b) or (c):



(a)



(b)



(c)

- 5 wherein:

R⁶ and R⁷ each independently represents a hydrogen or halogen atom, an alkyl or alkoxy group or a substituted or unsubstituted aryl group or when R⁶ and R⁷ are each attached to adjacent carbon atoms, then R⁶ and R⁷ together with the carbon atoms to which they are attached form a benzene ring wherein each carbon atom represented by R⁶ and R⁷ together is substituted or unsubstituted; and in the moiety of formula (a) X¹ represents oxygen or sulphur.

3. A compound according to claim 1 or claim 2, wherein A³ represents a moiety of formula -(CH₂)_m-CH(OR¹)-T wherein R¹, T and m are as defined in relation to claim 1.

4. A compound according to any one of claims 1 to 3, wherein R¹ is a moiety of formula -CH₂-CH₂-Ph.

5. A compound according to any one of claims 1 to 4, wherein R² represents OR³ in which R³ represents hydrogen or alkyl.


6. A compound according to any one of claims 1 to 5, wherein m is 1 and n is 2.

25

7. A compound according to any one of the examples 1 to 7 described herein, or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof.


8. A process for the preparation of a compound of formula (I), or a tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, which process comprises:

- 5 a) reacting a compound of formula (II):



(II)

- 10 wherein A^2 and Y are as defined in relation to formula (I);
 $A^{3'}$ represents a moiety of formula $-(CH_2)_m-CH(OR^{1'})-$ wherein $R^{1'}$ represents R^1 as defined in relation to formula (I) or a protected form thereof, and m is as defined in relation to formula (I), or A^3 represents a moiety of formula $-(CH_2)_{m-1}-CH=C(OR^{1'})-$ wherein $R^{1'}$ is as defined above;
 15 $R^{2'}$ represents R^2 as defined in relation to formula (I) or a protected form thereof and R^a is a moiety convertible to a moiety of formula (f):




(f)

- 20 wherein A^1 , X and n are as defined in relation to formula (I);
 with an appropriate reagent capable of converting R^a to the said moiety (f):
 (b) for a compound of formula (I) wherein A^3 represents a moiety of formula $-(CH_2)_m-CH(OR^1)-$:

25

- (i) by reacting an activated form of a compound of formula (VII):



(VII)


30

wherein A^1 , A^2 , X, Y, m and n are as defined in relation to formula (II) and R^9 is $R^{2'}$ as defined above or a protecting group, with a compound of formula (VIII);



wherein R^1 is as defined in relation to formula (I) and L^1 represents a leaving group or atom; or

10 (ii) by reacting a source of a carbene of formula (X):




15 wherein A^1 , A^2 , X, Y, m and n are as defined in relation to formula (I) and R^9 is $R^{2'}$ as defined above or a protecting group, with a compound of the above defined formula (V):




wherein $R^{1'}$ is defined in relation to formula (II);

(c) for a compound of formula (I) wherein A^3 represents a moiety of formula
25 $-(CH_2)_{m-1}-CH=C(OR^1)-$ or $-(CH_2)_m-CH(OR^1)-$, by reacting a compound of formula (XII):



wherein A^1 , A^2 , X , m and n are as defined in relation to formula (I), with a reagent capable of converting the CHO carbon atom into a group of the above defined formula $CH=C(OR^1)-Y.R^2$; and thereafter, if required, reducing the group $-CH=C(OR^1)-$ to provide a compound wherein A^3 represents a moiety of formula $-(CH_2)_m-CHOR^1-$;

(d) for a compound of formula (I) wherein A^3 represents a moiety of formula $-CH_2-CH(OR^1)-$ wherein R^1 represents alkyl, by hydrolysing a compound of formula (XV):



(XV)

wherein A^1 , A^2 , R^1 , X and n are as defined in relation to formula (I) to provide a compound of formula (I) wherein R^2 represents OH; and thereafter, if required, converting R^2 as OH into another R^2 ;


(e) for a compound of formula (I) wherein A^3 is $(CH_2)_m-CH(OR^1)-$ and R^2 is a C-linked aromatic heterocyclyl group, by reacting a compound of the above defined formula (XII) with an activated form of a compound of formula (XX)



(XX)

wherein het-CH is an aromatic heterocyclic group represented by R^2 which contains at least 1 carbon atom and thereafter converting the compound wherein R^1 is hydrogen into another R^1 ;

(f) for a compound of formula (I) wherein A^3 is $(CH_2)_m-CH(OR^1)-$ and R^2 is a C-linked tetrazolyl group, wherein the heterocyclyl group by reacting a compound of formula (XXI)



- wherein A^1 , A^2 , R^1 , X , m and n are as defined in relation to formula (I), with a
- 5 source of azide ions; and thereafter, if required, carrying out one or more of the following optional steps:
- (i) converting a compound of formula (I) to a further compound of formula (I);
 - (ii) removing any necessary protecting group;
 - 10 (iii) preparing a pharmaceutically acceptable salt of the compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.
9. A pharmaceutical composition comprising a compound of formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a
- 15 pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.
10. A compound of formula (I), or tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable
- 20 solvate thereof, for use as an active therapeutic substance.
11. A compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of hyperglycaemia,
- 25 hyperlipidaemia, hypertension, cardiovascular disease and/or certain eating disorders.
12. A method for the treatment and/or prophylaxis of hyperglycaemia hyperlipidaemia, hypertension, cardiovascular disease and/or certain eating
- 30 disorders in a human or non-human mammal which comprises administering an effective, non-toxic, amount of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a

pharmaceutically acceptable solvate thereof to a hyperglycaemic human or non-human mammal in need thereof.

- 5 13. The use of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperglycaemia, hyperlipidaemia, hypertension, cardiovascular disease and/or certain eating disorders.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 94/04112

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D263/58 C07D213/74 C07D239/42 A61K31/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,91 19702 (PFIZER INC.) 26 December 1991 see claims ---	1,2,9-13
A	WO,A,92 02520 (BEECHAM GROUP PLC) 20 February 1992 see claims ---	1,2,9-13
P,X	WO,A,94 01420 (SMITHKLINE BEECHAM CORPORATION) 20 January 1994 see claims -----	1-13

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

15 February 1995

Date of mailing of the international search report

22.02.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 cpo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 94/04112

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 12 is directed to a method of treatment of the human body,
the search has been carried out and based on the alleged effects of the
compounds.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
The definition of radicals A1 and R2 as aromatic heterocyclic group is too
broadly formulated to permit an adequate search. The search has essentially
been limited to the compounds of formula I which are supported by the
examples. (Claim 1 has been searched incompletely)
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/EP 94/04112

FIG. 1

FIG. 2

FIG. 3

FIG. 4

FIG. 5

FIG. 6

FIG. 7

FIG. 8

FIG. 9

FIG. 10

FIG. 11

FIG. 12

FIG. 13

FIG. 14

FIG. 15

FIG. 16

FIG. 17

FIG. 18

FIG. 19

FIG. 20

FIG. 21

FIG. 22

FIG. 23

FIG. 24

FIG. 25

FIG. 26

FIG. 27

FIG. 28

FIG. 29

FIG. 30

FIG. 31

FIG. 32

FIG. 33

FIG. 34

FIG. 35

FIG. 36

FIG. 37

FIG. 38

FIG. 39

FIG. 40

FIG. 41

FIG. 42

FIG. 43

FIG. 44

FIG. 45

FIG. 46

FIG. 47

FIG. 48

FIG. 49

FIG. 50

FIG. 51

FIG. 52

FIG. 53

FIG. 54

FIG. 55

FIG. 56

FIG. 57

FIG. 58

FIG. 59

FIG. 60

FIG. 61

FIG. 62

FIG. 63

FIG. 64

FIG. 65

FIG. 66

FIG. 67

FIG. 68

FIG. 69

FIG. 70

FIG. 71

FIG. 72

FIG. 73

FIG. 74

FIG. 75

FIG. 76

FIG. 77

FIG. 78

FIG. 79

FIG. 80

FIG. 81

FIG. 82

FIG. 83

FIG. 84

FIG. 85

FIG. 86

FIG. 87

FIG. 88

FIG. 89

FIG. 90

FIG. 91

FIG. 92

FIG. 93

FIG. 94

FIG. 95

FIG. 96

FIG. 97

FIG. 98

FIG. 99

FIG. 100

FIG. 101

FIG. 102

FIG. 103

FIG. 104

FIG. 105

FIG. 106

FIG. 107

FIG. 108

FIG. 109

FIG. 110

FIG. 111

FIG. 112

FIG. 113

FIG. 114

FIG. 115

FIG. 116

FIG. 117

FIG. 118

FIG. 119

FIG. 120

FIG. 121

FIG. 122

FIG. 123

FIG. 124

FIG. 125

FIG. 126

FIG. 127

FIG. 128

FIG. 129

FIG. 130

FIG. 131

FIG. 132

FIG. 133

FIG. 134

FIG. 135

FIG. 136

FIG. 137

FIG. 138

FIG. 139

FIG. 140

FIG. 141

FIG. 142

FIG. 143

FIG. 144

FIG. 145

FIG. 146

FIG. 147

FIG. 148

FIG. 149

FIG. 150

FIG. 151

FIG. 152

FIG. 153

FIG. 154

FIG. 155

FIG. 156

FIG. 157

FIG. 158

FIG. 159

FIG. 160

FIG. 161

FIG. 162

FIG. 163

FIG. 164

FIG. 165

FIG. 166

FIG. 167

FIG. 168

FIG. 169

FIG. 170

FIG. 171

FIG. 172

FIG. 173

FIG. 174

FIG. 175

FIG. 176

FIG. 177

FIG. 178

FIG. 179

FIG. 180

FIG. 181

FIG. 182

FIG. 183

FIG. 184

FIG. 185

FIG. 186

FIG. 187

FIG. 188

FIG. 189

FIG. 190

FIG. 191

FIG. 192

FIG. 193

FIG. 194

FIG. 195

FIG. 196

FIG. 197

FIG. 198

FIG. 199

FIG. 200

FIG. 201

FIG. 202

FIG. 203

FIG. 204

FIG. 205

FIG. 206

FIG. 207

FIG. 208

FIG. 209

FIG. 210

FIG. 211

FIG. 212

FIG. 213

FIG. 214

FIG. 215

FIG. 216

FIG. 217

FIG. 218

FIG. 219

FIG. 220

FIG. 221

FIG. 222

FIG. 223

FIG. 224

FIG. 225

FIG. 226

FIG. 227

FIG. 228

FIG. 229

FIG. 230

FIG. 231

FIG. 232

FIG. 233

FIG. 234

FIG. 235

FIG. 236

FIG. 237

FIG. 238

FIG. 239

FIG. 240

FIG. 241

FIG. 242

FIG. 243

FIG. 244

FIG. 245

FIG. 246

FIG. 247

FIG. 248

FIG. 249

FIG. 250

FIG. 251

FIG. 252

FIG. 253

FIG. 254

FIG. 255

FIG. 256

FIG. 257

FIG. 258

FIG. 259

FIG. 260

FIG. 261

FIG. 262

FIG. 263

FIG. 264

FIG. 265

FIG. 266

FIG. 267

FIG. 268

FIG. 269

FIG. 270

FIG. 271

FIG. 272

FIG. 273

FIG. 274

FIG. 275

FIG. 276

FIG. 277

FIG. 278

FIG. 279

FIG. 280

FIG. 281

FIG. 282

FIG. 283

FIG. 284

FIG. 285

FIG. 286

FIG. 287

FIG. 288

FIG. 289

FIG. 290

FIG. 291

FIG. 292

FIG. 293

FIG. 294

FIG. 295

FIG. 296

FIG. 297

FIG. 298

FIG. 299

FIG. 300

FIG. 301

FIG. 302

FIG. 303

FIG. 304

FIG. 305

FIG. 306

FIG. 307

FIG. 308

FIG. 309

FIG. 310

FIG. 311

FIG. 312

FIG. 313

FIG. 314

FIG. 315

FIG. 316

FIG. 317

FIG. 318

FIG. 319

FIG. 320

FIG. 321

FIG. 322

FIG. 323

FIG. 324

FIG. 325

FIG. 326

FIG. 327

FIG. 328

FIG. 329

FIG. 330

FIG. 331

FIG. 332

FIG. 333

FIG. 334

FIG. 335

FIG. 336

FIG. 337

FIG. 338

FIG. 339

FIG. 340

FIG. 341

FIG. 342

FIG. 343

FIG. 344

FIG. 345

FIG. 346

FIG. 347

FIG. 348

FIG. 349

FIG. 350

FIG. 351

FIG. 352

FIG. 353

FIG. 354

FIG. 355

FIG. 356

FIG. 357

FIG. 358

FIG. 359

FIG. 360

FIG. 361

FIG. 362

FIG. 363

FIG. 364

FIG. 365

FIG. 366

FIG. 367

FIG. 368

FIG. 369

FIG. 370

FIG. 371

FIG. 372

FIG. 373

FIG. 374

FIG. 375

FIG. 376

FIG. 377

FIG. 378

FIG. 379

FIG. 380

FIG. 381

FIG. 382

FIG. 383

FIG. 384

FIG. 385

FIG. 386

FIG. 387

FIG. 388

FIG. 389

FIG. 390

FIG. 391

FIG. 392

FIG. 393

FIG. 394

FIG. 395

FIG. 396

FIG. 397

FIG. 398

FIG. 399

FIG. 400

FIG. 401

FIG. 402

FIG. 403

FIG. 404

FIG. 405

FIG. 406

FIG. 407

FIG. 408

FIG. 409

FIG. 410

FIG. 411

FIG. 412

FIG. 413

FIG. 414

FIG. 415

FIG. 416

FIG. 417

FIG. 418

FIG. 419

FIG. 420

FIG. 421

FIG. 422

FIG. 423

FIG. 424

FIG. 425

FIG. 426

FIG. 427

FIG. 428

FIG. 429

FIG. 430

FIG. 431

FIG. 432

FIG. 433

FIG. 434

FIG. 435

FIG. 436

FIG. 437

FIG. 438

FIG. 439

FIG. 440

FIG. 441

FIG. 442

FIG. 443

FIG. 444

FIG. 445

FIG. 446

FIG. 447

FIG. 448

FIG. 449

FIG. 450

FIG. 451

FIG. 452

FIG. 453

FIG. 454

FIG. 455

FIG. 456

FIG. 457

FIG. 458

FIG. 459

FIG. 460

FIG. 461

FIG. 462

FIG. 463

FIG. 464

FIG. 465

FIG. 466

FIG. 467

FIG. 468

FIG. 469

FIG. 470

FIG. 471

FIG. 472

FIG. 473

FIG. 474

FIG. 475

FIG. 476

FIG. 477

FIG. 478

FIG. 479

FIG. 480

FIG. 481

FIG. 482

FIG. 483

FIG. 484

FIG. 485

FIG. 486

FIG. 487

FIG. 488

FIG. 489

FIG. 490

FIG. 491

FIG. 492

FIG. 493

FIG. 494

FIG. 495

FIG. 496

FIG. 497

FIG. 498

FIG. 499

FIG. 500

FIG. 501

FIG. 502

FIG. 503

FIG. 504

FIG. 505

FIG. 506

FIG. 507

FIG. 508

FIG. 509

FIG. 510

FIG. 511

FIG. 512

FIG. 513

FIG. 514

FIG. 515

FIG. 516

FIG. 517

FIG. 518

FIG. 519

FIG. 520

FIG. 521

FIG. 522

FIG. 523

FIG. 524

FIG. 525

FIG. 526

FIG. 527

FIG. 528

FIG. 529

FIG. 530

FIG. 531

FIG. 532

FIG. 533

FIG. 534

FIG. 535

FIG. 536

FIG. 537

FIG. 538

FIG. 539

FIG. 540

FIG. 541

FIG. 542

FIG. 543

FIG. 544

FIG. 545

FIG. 546

FIG. 547

FIG. 548

FIG. 549

FIG. 550

FIG. 551

FIG. 552

FIG. 553

FIG. 554

FIG. 555

FIG. 556

FIG. 557

FIG. 558

FIG. 559

FIG. 560

FIG. 561

FIG. 562

FIG. 563

FIG. 564

FIG. 565

FIG. 566

FIG. 567

FIG. 568

FIG. 569

FIG. 570

FIG. 571

FIG. 572

FIG. 573

FIG. 574

FIG. 575

FIG. 576

FIG. 577

FIG. 578

FIG. 579

FIG. 580

FIG. 581

FIG. 582

FIG. 583

FIG. 584

FIG. 585

FIG. 586

FIG. 587

FIG. 588

FIG. 589

FIG. 590

FIG. 591

FIG. 592

FIG. 593

FIG. 594

FIG. 595

FIG. 596

FIG. 597

FIG. 598

FIG. 599

FIG. 600

FIG. 601

FIG. 602

FIG. 603

FIG. 604

FIG. 605

FIG. 606

FIG. 607

FIG. 608

FIG. 609

FIG. 610

FIG. 611

FIG. 612

FIG. 613

FIG. 614

FIG. 615

FIG. 616

FIG. 617

FIG. 618

FIG. 619

FIG. 620

FIG. 621

FIG. 622

FIG. 623

FIG. 624

FIG. 625

FIG. 626

FIG. 627

FIG. 628

FIG. 629

FIG. 630

FIG. 631

FIG. 632

FIG. 633

FIG. 634

FIG. 635

FIG. 636

FIG. 637

FIG. 638

FIG. 639

FIG. 640

FIG. 641

FIG. 642

FIG. 643

FIG. 644

FIG. 645

FIG. 646

FIG. 647

FIG. 648

FIG. 649

FIG. 650

FIG. 651

FIG. 652

FIG. 653

FIG. 654

FIG. 655

FIG. 656

FIG. 657

FIG. 658

FIG. 659

FIG. 660

FIG. 661

FIG. 662

FIG. 663

FIG. 664

FIG. 665

FIG. 666

FIG. 667

FIG. 668

FIG. 669

FIG. 670

FIG. 671

FIG. 672

FIG. 673

FIG. 674

FIG. 675

FIG. 676

FIG. 677

FIG. 678

FIG. 679

FIG. 680

FIG. 681

FIG. 682

FIG. 683

FIG. 684

FIG. 685

FIG. 686

FIG. 687

FIG. 688

FIG. 689

FIG. 690

FIG. 691

FIG. 692

FIG. 693

FIG. 694

FIG. 695

FIG. 696

FIG. 697

FIG. 698

FIG. 699

FIG. 700

FIG. 701

FIG. 702

FIG. 703

FIG. 704

FIG. 705

FIG. 706

FIG. 707

FIG. 708

FIG. 709

FIG. 710

FIG. 711

FIG. 712

FIG. 713

FIG. 714

FIG. 715

FIG. 716

FIG. 717

FIG. 718

FIG. 719

FIG. 720

FIG. 721

FIG. 722

FIG. 723

FIG. 724

FIG. 725

FIG. 726

FIG. 727

FIG. 728

FIG. 729

FIG. 730

FIG. 731

FIG. 732

FIG. 733

FIG. 734

FIG. 735

FIG. 736

FIG. 737

FIG. 738

FIG. 739

FIG. 740

FIG. 741

FIG. 742

FIG. 743

FIG. 744

FIG. 745

FIG. 746

FIG. 747

FIG. 748

FIG. 749

FIG. 750

FIG. 751

FIG. 752

FIG. 753

FIG. 754

FIG. 755

FIG. 756

FIG. 757

FIG. 758

FIG. 759

FIG. 760

FIG. 761

FIG. 762

FIG. 763

FIG. 764

FIG. 765

FIG. 766

FIG. 767

FIG. 768

FIG. 769

FIG. 770

FIG. 771

FIG. 772

FIG. 773

FIG. 774

FIG. 775

FIG. 776

FIG. 777

FIG. 778

FIG. 779

FIG. 780

FIG. 781

FIG. 782

FIG. 783

FIG. 784

FIG. 785

FIG. 786

FIG. 787

FIG. 788

FIG. 789

FIG. 790

FIG. 791

FIG. 792

FIG. 793

FIG. 794

FIG. 795

FIG. 796

FIG. 797

FIG. 798

FIG. 799

FIG. 800

FIG. 801

FIG. 802

FIG. 803

FIG. 804

FIG. 805

FIG. 806

FIG. 807

FIG. 808

FIG. 809

FIG. 810

FIG. 811

FIG. 812

FIG. 813

FIG. 814

FIG. 815

FIG. 816

FIG. 817

FIG. 818

FIG. 819

FIG. 820

FIG. 821

FIG. 822

FIG. 823

FIG. 824

FIG. 825

FIG. 826

FIG. 827

FIG. 828

FIG. 829

FIG. 830

FIG. 831

FIG. 832

FIG. 833

FIG. 834

FIG. 835

FIG. 836

FIG. 837

FIG. 838

FIG. 839

FIG. 840

FIG. 841

FIG. 842

FIG. 843

FIG. 844

FIG. 845

FIG. 846

FIG. 847

FIG. 848

FIG. 849

FIG. 850

FIG. 851

FIG. 852

FIG. 853

FIG. 854

FIG. 855

FIG. 856

FIG. 857

FIG. 858

FIG. 859

FIG. 860

FIG. 861

FIG. 862

FIG. 863

FIG. 864

FIG. 865

FIG. 866

FIG. 867

FIG. 868

FIG. 869

FIG. 870

FIG. 871

FIG. 872

FIG. 873

FIG. 874

FIG. 875

FIG. 876

FIG. 877

FIG. 878

FIG. 879

FIG. 880

FIG. 881

FIG. 882

FIG. 883

FIG. 884

FIG. 885

FIG. 886

FIG. 887

FIG. 888

FIG. 889

FIG. 890

FIG. 891

FIG. 892

FIG. 893

FIG. 894

FIG. 895

FIG. 896

FIG. 897

FIG. 898

FIG. 899

FIG. 900

FIG. 901

FIG. 902

FIG. 903

FIG. 904

FIG. 905

FIG. 906

FIG. 907

FIG. 908

FIG. 909

FIG. 910

FIG. 911

FIG. 912

FIG. 913

FIG. 914

FIG. 915

FIG. 916

FIG. 917

FIG. 918

FIG. 919

FIG. 920

FIG. 921

FIG. 922

FIG. 923

FIG. 924

FIG. 925

FIG. 926

FIG. 927

FIG. 928

FIG. 929

FIG. 930

FIG. 931

FIG. 932

FIG. 933

FIG. 934

FIG. 935

FIG. 936

FIG. 937

FIG. 938

FIG. 939

FIG. 940

FIG. 941

FIG. 942

FIG. 943

FIG. 944

FIG. 945

FIG. 946

FIG. 947

FIG. 948

FIG. 949

FIG. 950

FIG. 951

FIG. 952

FIG. 953

FIG. 954

FIG. 955

FIG. 956

FIG. 957

FIG. 958

FIG. 959

FIG. 960

FIG. 961

FIG. 962

FIG. 963

FIG. 964

FIG. 965

FIG. 966

FIG. 967

FIG. 968

FIG. 969

FIG. 970

FIG. 971

FIG. 972

FIG. 973

FIG. 974

FIG. 975

FIG. 976

FIG. 977

FIG. 978

FIG. 979

FIG. 980

FIG. 981

FIG. 982

FIG. 983

FIG. 984

FIG. 985

FIG. 986

FIG. 987

FIG. 988

FIG. 989

FIG. 990

FIG. 991

FIG. 992

FIG. 993

FIG. 994

FIG. 995

FIG. 996

FIG. 997

FIG. 998

FIG. 999

FIG. 1000

FIG. 1001

FIG. 1002

FIG. 1003

FIG. 1004

FIG. 1005

FIG. 1006

FIG. 1007

FIG. 1008

FIG. 1009

FIG. 1010

FIG. 1011

FIG. 1012

FIG. 1013

FIG. 1014

FIG. 1015

FIG. 1016

FIG. 1017

FIG. 1018

FIG. 1019

FIG. 1020

FIG. 1021

FIG. 1022

FIG. 1023

FIG. 1024

FIG. 1025

FIG. 1026

FIG. 1027

FIG. 1028

FIG. 1029

FIG. 1030

FIG. 1031

FIG. 1032

FIG. 1033

FIG. 1034

FIG. 1035

FIG. 1036

FIG. 1037

FIG. 1038

FIG. 1039

FIG. 1040

FIG. 1041

FIG. 1042

FIG. 1043

FIG. 1044

FIG. 1045

FIG. 1046

FIG. 1047

FIG. 1048

FIG. 1049

FIG. 1050

FIG. 1051

FIG. 1052

FIG. 1053

FIG. 1054

FIG. 1055

FIG. 1056

FIG. 1057

FIG. 1058

FIG. 1059

FIG. 1060

FIG. 1061

FIG. 1062

FIG. 1063

FIG. 1064

FIG. 1065

FIG. 1066

FIG. 1067

FIG. 1068

FIG. 1069

FIG. 1070

FIG. 1071

FIG. 1072

FIG. 1073

FIG. 1074

FIG. 1075

FIG. 1076

FIG. 1077

FIG. 1078

FIG. 1079

FIG. 1080

FIG. 1081

FIG. 1082

FIG. 1083

FIG. 1084

FIG. 1085

FIG. 1086

FIG. 1087

FIG. 1088

FIG. 1089

FIG. 1090

FIG. 1091

FIG. 1092

FIG. 1093

FIG. 1094

FIG. 1095

FIG. 1096

FIG. 1097

FIG. 1098

FIG. 1099

FIG. 1100

FIG. 1101

FIG. 1102

FIG. 1103

FIG. 1104

FIG. 1105

FIG. 1106

FIG. 1107

FIG. 1108

FIG. 1109

FIG. 1110

FIG. 1111

FIG. 1112

FIG. 1113

FIG. 1114

FIG. 1115

FIG. 1116

FIG. 1117

FIG. 1118

FIG. 1119

FIG. 1120

FIG. 1121

FIG. 1122

FIG. 1123

FIG. 1124

FIG

THIS PAGE BLANK (USPTO)